Scientists unveil most detailed atlas of the basal ganglia
Researchers across nine countries have published the most comprehensive multi-species cellular atlas of the basal ganglia, a brain region central to movement, emotion and several major diseases. The openly available dataset could accelerate work on Parkinson’s, Huntington’s, schizophrenia, bipolar disorder, addiction and autism.
Why it matters: - The basal ganglia are tied to Parkinson’s disease, Huntington’s disease, schizophrenia, bipolar disorder and addiction. - The new atlas gives researchers a much sharper map of the cell types and molecular signals in a region that is critical for movement, habit formation, decision making and emotion. - The dataset is openly available, which could speed up follow-on research across the global neuroscience community.
What happened: - Dozens of labs and hundreds of scientists across nine countries and more than 50 institutions released the most detailed multi-species cellular atlas of the basal ganglia to date. - Researchers profiled 25.5 million cells using single-cell molecular profiling technologies. - The study set includes 21.0 million human cells, 3.0 million cells from rhesus and cynomolgus macaques, and 1.5 million marmoset cells. - The findings appeared today in a package of 26 studies in the Cell Press family of journals. - The work marks the first major working model of a standardized, cross-species brain cell reference atlas.
The details: - The atlas is the first major output from the BRAIN Initiative Cell Atlas Network, or BICAN, which aims to build a complete parts list of cell types across the human brain. - Researchers used a common reference system to classify and analyze the brain’s complexity across studies, labs and data types. - The project combined gene expression, epigenetic regulation, spatial analysis and physiological properties. - The different approaches largely agreed with one another, strengthening confidence in the cellular classification. - The atlas is designed as a shared framework for the field rather than a single-lab resource. - The work is funded by the NIH’s Brain Research Through Advancing Innovative Neurotechnologies Initiative, or BRAIN Initiative.
Between the lines: - The project addresses a core problem in brain research: disease often appears to act at the level of specific cell types, but the field has lacked a common map for comparing those cells across species and methods. - The new framework may help researchers move from broad disease associations to more precise targets. - The scale of the collaboration shows how much modern neuroscience now depends on shared standards and open data.
What's next: - Researchers will use the atlas as a reference for deeper studies of brain function and disease. - The open dataset is expected to support new discoveries beyond the basal ganglia. - BICAN’s broader effort to map all cell types in the human brain continues, with this atlas serving as a major milestone.
The bottom line: - The field now has a high-resolution, cross-species baseline for one of the brain’s most disease-relevant regions, and that could reshape how scientists study brain disorders.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Science Press Releases
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.